Adverum Biotechnologies Inc (ADVM NASDAQ) stock market data APIs
$4.2654
0.08(1.9%)
as of November 5, 2025
Try our APIs with
free plan!
Adverum Biotechnologies Inc Financial Data Overview
Price chart is built with
Anychart
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Prev. Close
4.2654
Open
4.3404
High
4.3152
Low
4.3177
52 wk Range
1.78-8.18
Market Cap
95 032 K
Shares Outstanding
21 998 K
Revenue
1 000 K
EPS
-2.34
Beta
0.868
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Adverum Biotechnologies Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Adverum Biotechnologies Inc data using free add-ons & libraries
Get Adverum Biotechnologies Inc Fundamental Data
Adverum Biotechnologies Inc Fundamental data includes:
- Net Revenue: 1 000 K
- EBITDA: -172 214 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-11
- EPS/Forecast: -2.284
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Adverum Biotechnologies Inc News
New
Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales
Eli Lilly and Company LLY reported third-quarter 2025 adjusted earnings per share (“EPS”) of $7.02, which beat the Zacks Consensus Estimate of $6.02 per share. In the year-ago quarter, Lilly recor...
Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings
Eli Lilly and Company LLY will report its third-quarter 2025 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $16.01 billion and $6.02 per sha...
Key deals this week: United States Antimony, Grindr, Eli Lilly, Hologic and more
Here's a list of key deals reported across sectors this week: Entities tied to Makarora Management, along with Ares Alternative Credit funds, have agreed to acquire [https://seekingalpha.com/pr/20279...
Halper Sadeh LLC Encourages ADVM, MOFG, HSII Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or bre...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
